Delivery Order SPE2DB22D3301-SPE2DB26FX3NM
- Not listed
- The Defense Logistics Agency (DLA) awarded a $1,479.44 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Methylphenidate ER 36 mg tablets in a quantity of 100 units. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 29, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Methylphenidate ER 36 mg tablets (100-count bottles) with a contract value of $1,052.28. This competitively awarded, non-set-aside delivery order is firm fixed price and scheduled for completion by August 27, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $1,073.04 to AmerisourceBergen Drug Corp for the supply of Methylphenidate ER 36 mg tablets (100-count units). This order, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a firm fixed-price, competitively awarded contract with no set-aside designation. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,186.76 for Methylphenidate ER 36 mg tablets (100-count) on August 1, 2025, with completion scheduled for August 4, 2025. This competitively awarded, firm fixed-price delivery order was placed without set-aside designations and is being performed at the contractor's facility in Conshohocken, Pennsylvania. The pharmaceutical product supports federal medical supply requirements, primarily serving military...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Methylphenidate ER 36 mg tablets in quantities of 100 tablets, with a ceiling value of $11,400.02. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitive award to the prime contractor. The delivery order is expected to be completed by September 18, 2025, and will be performed at the vendor's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Methylphenidate ER 36 mg tablets (100-count bottles) under a firm fixed-price contract valued at $2,729.30. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Methylphenidate ER 36 mg tablets (100-count units) with a ceiling value of $1,291.98. The contract is classified as firm fixed price with an ultimate completion date of September 4, 2025. No set-aside designation was used for this competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill the order from its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Methylphenidate ER 36 mg tablets (100 count) with a ceiling value of $2,469.41. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 25, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Methylphenidate ER 36 mg tablets (100-count units) with a ceiling value of $2,855.75. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award based on open competition. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office. The contract is scheduled...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,332.89 for Methylphenidate ER 54 mg tablets (100-count bottles) on September 23, 2025, with completion scheduled for September 24, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a direct fulfillment of pharmaceutical supply needs for federal military and healthcare systems. The work will be performed at AmerisourceBergen's corporate office...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB26FX3NMDelivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,774.51 on October 20, 2025, for the supply of Methylphenidate ER 36 mg tablets in quantities of 100 units. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by October 21, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999,999,999.00 pharmaceutical prime vendor agreement extending through December 2026. The IDC enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare systems worldwide. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen Drug Corp maintains a significant portfolio of delivery orders with DLA covering medications across multiple therapeutic domains to support Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 10/20/25 |